Icosavax Announces Positive Topline Interim Phase 1 Results for Bivalent VLP Vaccine…
<!-- Name:DistributionId Value:8844301 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
Nasdaq:ICVX
Icosavax Provides Corporate Update and Anticipated Milestones for 2023
- Recently reported positive six-month immunogenicity data for IVX-121 against RSV; first clinical evidence of potential differentiation on durability with company’s VLP platform - - Phase…
Icosavax Initiates Phase 1 Trial of IVX-A12 Against RSV and hMPV in Older Adults
- IVX-A12 is the first combination bivalent vaccine candidate against both respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) to reach clinical stage - - Phase 1 topline…
Icosavax Announces Positive Topline Interim Phase 1/1b Results for VLP Vaccine…
- IVX-121 demonstrated robust immunologic response to RSV, with comparable Geometric Mean Titer (GMT) levels achieved at Day 28 in both young and older adult groups - - IVX-121 was…
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
- Immunologic response observed in both SARS-CoV-2 naive and previously vaccinated subjects, but lower than expected and inconsistent with known data on company’s platform and VLP…